Webinar: Avalere Research on Health Plan - Life Science OBCs: The Rise in Outcomes Based Contracts

  • Sale
  • Regular price $260.00

Wednesday, October 30, 2019, at 1 PM - 2 PM Eastern

  • Avalere research findings on payer and life science OBCs
  • Perceived challenges with OBCs
  • OBC considerations for new/existing products, and therapeutic areas of focus
  • OBC cost savings expectations timelines
  • Potential usage of ancillary services under OBCs
  • Methods to measure value and financial incentives

    Faculty: Sarah Butler Donovan, Head of Client Solutions, Marketing, and Operations, Avalere; John E. Linnehan, Practice Director, Health Economics & Advanced Analytics, Avalere; and Michael Schneider, Principal, Avalere

    Need a Printable Form? Download a registration form you can fax or mail

    Learn more by watching the video below:


    Outcomes-based contracts (OBC)s can provide payers and life sciences companies with an innovative and effective approach to pursue high-value care that is ultimately beneficial for patients. This type of contracting structure is an agreement between a health plan and drug and device manufacturers that ties product reimbursement to clinical, quality, utilization, or financial outcomes. Over time, a greater willingness has been demonstrated from both health plans and life sciences companies to pursue and execute OBCs.

    New Avalere research finds that 59% of payers have executed an outcomes-based contract. When Avalere first conducted this survey in 2017, 24% of health plans had an OBC in place. Avalere’s survey also found that nearly 60% of health plans with an OBC already in place cited cost savings and clinical improvement as the top advantages of OBCs. Both of these rates have increased since the survey was first conducted in 2017. The capture of real-world information and improved payer–manufacturer relationships were also notable areas of growth.

    Avalere found that as payers continue to gain greater experience with outcomes-based contracts, their design and measurement of these contracts are becoming more refined and efficient, and that they have translated into improved cost savings and patient outcomes.

    Avalere conducted a 43-question survey of U.S. health plans and pharmacy benefits managers (PBMs) between July 19, 2019 and August 5, 2019. Avalere designed the survey to better gauge and measure current awareness, use, experience, and attitudes toward outcomes-based contracting. Respondents were recruited from a comprehensive panel of health plan and PBM representatives and then screened to determine eligibility.  A total of 50 qualified payers participated in the survey.

    Avalere’s survey also examined the perceived challenges with OBCs, considerations for looking at a new/existing product, therapeutic areas of focus, cost savings expectations timeline, usage of ancillary services, methods used to measure value, and financial incentives used to execute OBCs.

    Please join us on Wednesday, October 30, 2019, at 1 PM Eastern as Avalere’s Sarah Donovan, John Linnehan and Michael Schneider discuss Avalere OBC research findings, insights and implications, in the HealthcareWebSummit event: Avalere Research on Health Plan - Life Science OBCs: The Rise in Outcomes Based Contracts.

    Cure for the Common Webinar

    In addition to the main faculty presentation, this event includes a fun whiteboard drawing format opening video, a brief moderated faculty interview, and concluding live audience questions and answers. The day before the event, you'll receive login information, including downloadable companion presentation slides.

    Just after the event, you'll receive a follow-up request for feedback, also offering an opportunity to provide any final questions that can be forwarded to the faculty. Also, if you need support before, during or after the event, you can contact HealthcareWebSummit staff at any time.

    Learning Objectives

    After attending this webinar, attendees will be able to:

    • Review Avalere research findings on levels of participation and parameters of payer and life science organization OBCs
    • Examine the perceived challenges with OBCs
    • Peruse considerations for looking at a new/existing product, and therapeutic areas of focus for OBCs
    • Ascertain OBC cost savings expectations timelines
    • Contemplate potential usage of ancillary services under OBCs
    • Explore methods used to measure value and financial incentives used to execute OBCs
    • Engage in interactive learning through online question submission, attendee feedback and opportunity for post-event follow up questions.

        Who Should Attend

        Interested attendees would include:

        • C-Suite Executives
        • OBC and Value Based Contracting Executives and Staff
        • Pharmaceutical Benefit Management Executives and Staff
        • Managed Market Executives and Staff
        • Planning and Strategic Executives and Staff
        • Outcomes Based Analytics Staff
        • Business Intelligence Staff
        • Other Interested Parties

         Attendees would represent organizations including:

        • Health Plans
        • Life Sciences Organizations
        • PBMs
        • Third Party Administrators
        • Employers
        • Clinically Integrated Networks
        • Solutions Providers
        • Associations, Institutes and Research Organizations
        • Media
        • Other Interested Organizations


              Individual Registration Fee: $195. Post-event materials, with video of slides synchronized with speaker audio, plus presentation pdf file: $45 for attendees; $260 for non-attendees after the event. Register above or download a registration form.

              You can also register by phone: 209.577.4888. Corporate Site licensing also available. We look forward to your attendance!


              Hank Osowski

              Sarah Butler Donovan
              Head of Client Solutions, Marketing, and Operations

              Sarah Butler Donovan leads the Client Solutions team, which includes account management, business development, and sales for life sciences, health plan, and provider clients.

              She specializes in evidence-based medicine, value-based contracting, and strategy development. Sarah is a frequent speaker about healthcare trends and is an industry expert on value-based contracting.

              Prior to joining Avalere, Sarah held positions at the Cato Institute, the Brookings Institution, McGuireWoods LLP, and Goodell, DeVries, Leech & Dann LLP.

              Sarah has an MHS in Health Policy from the Johns Hopkins University Bloomberg School of Public Health and a BA in History from the University of Richmond.

              John E. Linnehan
              Practice Director, Health Economics & Advanced Analytics

              John E. Linnehan leads Avalere’s Health Economics and Advanced Analytics Practice, a team of consultants, strategists, and data scientists focused on driving healthcare improvement through value demonstration, stakeholder engagement, predictive and applied analytics, and data innovations.

              His team of experts, extracting knowledge and insights from one of the largest US patient data sources, supports a diverse array of healthcare stakeholders including commercial, HEOR, medical, and public policy professionals at biopharmaceutical companies, device manufacturers, health plans, delivery networks, patient advocacy groups, and medical societies.

              John’s technical expertise is grounded in HEOR and using evidence-based medicine to achieve commercial aims and long-term strategic planning. He has a strong background in sales and new business development, and regularly advises healthcare executives on maximizing commercial and medical potential within a dynamic and complex healthcare ecosystem. An accomplished public speaker, he presents regularly at conferences, national meetings, and academic environments.

              Prior to joining Avalere, John served as a health economist at Oxford Outcomes (now part of ICON) and a research associate within the Health Economics practice at United BioSource Corporation (now Evidera).

              John holds an MPH from The Johns Hopkins Bloomberg School of Public Health, an MBA from The Johns Hopkins Carey Business School, and a BA in biology from the University of Pennsylvania. His research has been published in numerous peer-reviewed journals.

              Hank Osowski

              Michael Schneider

              Mike Schneider has joined the Avalere commercialization and regulatory strategies team as a principal. He is working with life sciences companies to help them develop and implement market access strategies.

              Schneider comes to Avalere with extensive experience in manufacturing and pharmacy benefits. He spent 9 years at CVS Caremark where he was the director of industry relations and was responsible for trade strategy development, rebate negotiations, and contract execution for CVS Caremark’s Medicare Part D plans and those of its clients.

              He has served as a national account director for Otsuka Pharmaceuticals and SC Pharmaceuticals, a startup device manufacturer. He spent 10 years working across a number of pharmaceutical manufacturers in sales and account management roles.